30 closest matches · ranked by relevance
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Advanced Solid Tumors
Primary: Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) — 288.55; 105.8 μg·h/L/mg
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
Neoplasms · Neoplasm Metastasis · Triple Negative Breast Neoplasms
Primary: Phase 1: Maximum Tolerated Dose — 25 milligram (mg)
Solid Tumors
Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Advanced Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Lipotecan — 50 mg/m^2
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose